HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) stock shows moves up of 11.86% and traded at a price of $2.17 in preceding trading session.
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) reported that a new Master Collaboration Contract for translational programs with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The Master Collaboration Contract complements the previously reported Master Companion Diagnostic Contract with Merck KGaA, Darmstadt, Germany and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the United States and Canada.
President and Chief Executive Officer of HTG, TJ Johnson said, “We are pleased to expand our relationship with Merck KGaA, Darmstadt, Germany, into earlier research stages of their programs, and have already begun work on an initial custom assay development program. “They are terrific partners, and we appreciate the confidence their teams have placed in us and our HTG EdgeSeq technology.”
Under the first program statement of work, HTG plans to develop and manufacture a custom profiling assay to support biomarker research for six indications within Merck KGaA, Darmstadt, Germany’s drug development pipeline. The assay is expected to be kitted for use on HTG EdgeSeq instruments purchased by Merck KGaA and/or their contract research organization partners.
Its 52-week range quite noticeable, lower range was $80.83% and hit highest level of $-83.62%. The overall volume in the last trading session was 1.27 Million shares. The liquidity position of firm is on noticeable level, as its current ratio was calculated as 1.00 at the same time.
Shares of Credit Suisse Group AG (NYSE:CS) at the time when day-trade ended the stock finally fell -0.75% to close at $17.76. Pomerantz LLP is investigating claims on behalf of investors of Credit Suisse Group A.G. (NYSE: CS).
On February 4, 2016, Credit Suisse reported its Fourth Quarter and Full Year 2015 financial results, which included a massive $633 million write-down from the sale of the Bank’s outsized, illiquid distressed debt and CLO positions, an incredible loss that would swell to nearly $1 billion in the ensuing weeks. In the wake of Credit Suisse’s revelations, the price of the Bank’s ADRs declined from a close of $16.69 on February 3, 2016 to a close of $14.89 on February 4, 2016, an 11% drop that wiped out around $230 million in market capitalization.
The volatility tends to amount of risk or uncertainty about size of changes in a security’s value; a higher volatility denotes that a security’s value can potentially be spread out over a larger range of values. The price volatility of CS was 0.97% for a week and 1.10% for a month as well as price volatility’s Average True Range for 14 days was 0.23. Shares price isolated positively from its 50 days moving average with 7.07% and remote positively from 200 days moving average with 17.08%.